Anti-BCRABL [7c6]
Invented at Queen Mary University of London
Anti-BCRABL, Recombinant [7c6]
Invented at Queen Mary University of London
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153261 |
| Applications | IF IP WB |
| Antigen/Gene or Protein Targets | BCRABL |
| Reactivity | Human |
| Relevance |
Recombinant antibody directed against BCR-ABL oncoprotein. Background and Research Application The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity. This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein. |
| Host | Mouse |
| Immunogen | Bcr686 thyroglobulin conjugate |
| Subclass | IgG2a |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Research Area | Cancer |
| Immunogen UniProt ID | Q62199 |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Six products based on this clone: - Anti-BCR-ABL [7c6], Mouse IgG2a, Kappa - Anti-BCR-ABL [7c6], Mouse IgG2a, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors - Anti-BCR-ABL [7c6], Rabbit IgG, Kappa - Anti-BCR-ABL [7c6], Human IgG1, Kappa - Anti-BCR-ABL [7c6], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. - Anti-BCR-ABL [7c6], Human IgG4-S228P, Kappa Concentration 1mg/ml as standard |
References: 1 entry
Original hybridoma first published in: Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.
Add a reference
References: 1 entry
Original hybridoma first published in: Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.
Add a reference
